IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 26-50 out of 1244.

<< < 1 | 2 | 3 | 4 | 5 | 6 > >>

Public Release: 26-Aug-2014
Deutsches Ärzteblatt International
Symptoms after breast cancer surgery need to be treated on an individual basis
For those affected, breast cancer is a dramatic diagnosis. Patients often have to endure chemotherapy and surgery, which, depending on the individual scenario, may mean breast conserving surgery or breast removal -- mastectomy. In the aftermath, many women experience symptoms such as pain, fatigue/exhaustion, or sleep disturbances. However, the symptoms are highly individual, as Stefan Feiten and colleagues emphasize in a recent study reported in Deutsches Ärzteblatt International.

Contact: Stefan Feiten
s.feiten@invo-koblenz.de
Deutsches Aerzteblatt International

Public Release: 26-Aug-2014
BJU International
US has seen widespread adoption of robot-assisted cancer surgery to remove the prostate
A new study reveals that the US has experienced widespread adoption of robot-assisted prostate removal surgery to treat prostate cancer in recent years. The BJU International study also found that while such surgeries are more expensive than traditional surgeries, their costs are decreasing over time.

Contact: Evelyn Martinez
sciencenewsroom@wiley.com
201-748-6358
Wiley

Public Release: 26-Aug-2014
Nature Methods
New tool to probe cancer's molecular make-up
Researchers from the Cancer Research UK Manchester Institute based at the University of Manchester -- part of the Manchester Cancer Research Centre -- and the Institute of Cancer Research, London, looked at protein kinases, molecules that control various aspects of cellular function.
Biotechnology and Biological Sciences Research Council/Pfizer CASE Studentship, Cancer Research UK

Contact: Alison Barbuti
alison.barbuti@manchester.ac.uk
44-161-275-8383
University of Manchester

Public Release: 25-Aug-2014
Genome Medicine
Cancer leaves a common fingerprint on DNA
Regardless of their stage or type, cancers appear to share a telltale signature of widespread changes to the so-called epigenome, according to a team of researchers. In a study published online in Genome Medicine on Aug. 26, the investigators say they have found widespread and distinctive changes in a broad variety of cancers to chemical marks known as methyl groups attached to DNA, which help govern whether genes are turned 'on' or 'off.'
NIH/National Human Genome Research Institute, NIH/National Cancer Institute, NIH/National Institute of General Medical Sciences, NIH/National Center for Research Resources

Contact: Shawna Williams
shawna@jhmi.edu
410-955-8236
Johns Hopkins Medicine

Public Release: 25-Aug-2014
JAMA Internal Medicine
Study shows 25 percent fewer opioid-related deaths in states allowing medical marijuana
On average, states allowing the medical use of marijuana have lower rates of deaths resulting from opioid analgesic overdoses than states without such laws. A new multi-institutional study, published in JAMA Internal Medicine and led by researchers at the Perelman School of Medicine at the University of Pennsylvania, shows that on average, the 13 states allowing the use of medical marijuana had a 24.8 percent lower annual opioid overdose mortality rate after the laws were enacted than states without the laws.
National Institutes of Health

Contact: Katie Delach
katie.delach@uphs.upenn.edu
215-349-5964
University of Pennsylvania School of Medicine

Public Release: 25-Aug-2014
Genome Biology
RNA sequence could help doctors to tailor unique prostate cancer treatment programs
Sequencing RNA, not just DNA, could help doctors predict how prostate cancer tumors will respond to treatment, according to research published in the open-access journal Genome Biology. Because a tumor's RNA shows the real time changes a treatment is causing, the authors think this could be a useful tool to aid diagnosis and predict which treatment will most benefit individual cancer patients.

Contact: Shane Canning
shane.canning@biomedcentral.com
44-203-192-2429
BioMed Central

Public Release: 25-Aug-2014
Journal of Cell Biology
Deploying exosomes to win a battle of the sexes
A new study provides further detail into how male fruit flies ensure reproductive success by deploying exosomes to alter the mating behavior of females. The findings also identify a signaling pathway that might play a role in human cancers of tissues that secrete exosomes, such as the prostate and breast.
Wellcome Trust, Oxford Cancer Research Centre, Cancer Research UK, Biotechnology and Biological Sciences Research Council, Medical Research Council, and others

Contact: Rita Sullivan King
news@rupress.org
212-327-8603
Rockefeller University Press

Public Release: 25-Aug-2014
Cell Reports
Drug used for DNA repair defects could treat leukemia and other cancers more effectively
A team of scientists led by research associate professor Motomi Osato and professor Yoshiaki Ito from the Cancer Science Institute of Singapore at the National University of Singapore found that a drug originally designed for killing a limited type of cancer cells with DNA repair defects could potentially be used to treat leukemia and other cancers.

Contact: Kimberley Wang
kimberley.wang@nus.edu.sg
National University of Singapore

Public Release: 25-Aug-2014
CANCER
Medicaid reimbursements may affect cancer screening rates among beneficiaries
A recent study has found that in states with higher Medicaid payments for office visits, Medicaid beneficiaries were more likely to be screened for breast, cervical, and colorectal cancer.

Contact: Evelyn Martinez
sciencenewsroom@wiley.com
Wiley

Public Release: 25-Aug-2014
JAMA Pediatrics
Weekend hospitalization linked to longer stay for pediatric leukemia patients
Weekend admission to the hospital for pediatric patients newly diagnosed with leukemia was associated with a longer length of stay, slightly longer wait to start chemotherapy and higher risk for respiratory failure but weekend admissions were not linked to an increased risk for death.

Contact: Rachel Salis-Silverman
salis@email.chop.edu
267-426-6063
The JAMA Network Journals

Public Release: 25-Aug-2014
Molecular and Cellular Biology
New biomarker highly promising for predicting breast cancer outcomes
A protein named p66ShcA shows promise as a biomarker to identify breast cancers with poor prognoses, according to research published ahead of print in the journal Molecular and Cellular Biology.

Contact: Jim Sliwa
jsliwa@asmusa.org
202-942-9297
American Society for Microbiology

Public Release: 25-Aug-2014
Nature Genetics
UNC Lineberger researchers develop new approach to identify 'drivers' of cancer
UNC Lineberger Comprehensive Cancer Center researchers have developed a new integrated approach to pinpoint the genetic 'drivers' of cancer, uncovering eight genes that could be viable for targeted breast cancer therapy.

Contact: Katy Jones
katy_jones@unc.edu
919-883-7848
University of North Carolina Health Care

Public Release: 25-Aug-2014
ACM Special Interest Group on Knowledge Discovery and Data Mining Conference
Study shows promise in automated reasoning, hypothesis generation over complete medical literature
With approximately 50 million scientific papers available in public databases -- and a new one publishing nearly every 30 seconds -- scientists cannot know about every relevant study when they are deciding where to take their research next. A new tool in development by computational biologists at Baylor College of Medicine and analytics experts at IBM research and tested as a 'proof-of-principle' may one day help researchers mine all public medical literature and formulate hypotheses that promise the greatest reward when pursuing new scientific studies.

Contact: Glenna Picton
picton@bcm.edu
713-798-4710
Baylor College of Medicine

Public Release: 25-Aug-2014
Oncotarget
Finding keys to glioblastoma therapeutic resistance
Researchers at the University of California, San Diego School of Medicine have found one of the keys to why certain glioblastomas -- the primary form of a deadly brain cancer -- are resistant to drug therapy. The answer lies not in the DNA sequence of the tumor, but in its epigenetic signature. These findings have been published online as a priority report in the journal Oncotarget.
Sontag Foundation, Burroughs Wellcome Foundation, Kimmel Foundation, Doris Duke Foundation, Forbeck Foundation

Contact: Scott LaFee
slafee@ucsd.edu
619-543-6163
University of California - San Diego

Public Release: 25-Aug-2014
Journal of Clinical Oncology
Kite Pharma announces positive results in patients with aggressive non-Hodgkin's lymphoma
Kite Pharma Inc., a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy products for the treatment of cancer, today announced the publication of clinical results in a cohort of patients demonstrating the potential to treat aggressive non-Hodgkin's lymphoma with an anti-CD19 chimeric antigen receptor T cell therapy.
Kite Pharma

Contact: Justin Jackson
jjackson@burnsmc.com
212-213-0006 x327
Burns McClellan

Public Release: 25-Aug-2014
Journal of Cell Biology
Scientists uncover navigation system used by cancer, nerve cells
A study in C. elegans worms identifies a 'roving detection system' on the surface of worm cells that may point to new ways of treating diseases like cancer, Parkinson's disease and amyotrophic lateral sclerosis. The study sheds light on the molecular mechanisms that enable both normal and cancerous cells to break through normal tissue boundaries and burrow into other tissues and organs.
National Institutes of Health, Pew Charitable Trusts

Contact: Robin Ann Smith
ras10@duke.edu
919-681-8057
Duke University

Public Release: 24-Aug-2014
Nature Medicine
Study suggests repurposing anti-depressant medication to target medulloblastoma
An international research team reports in Nature Medicine a novel molecular pathway that causes an aggressive form of medulloblastoma, and suggests repurposing an anti-depressant medication to target the new pathway may help combat one of the most common brain cancers in children. The scientists say their laboratory findings in mouse models of the disease could lead to a more targeted and effective molecular therapy that would also reduce the harmful side effects of current treatments.
National Institutes of Health, Canadian Institutes of Health Research

Contact: Nick Miller
nicholas.miller@cchmc.org
513-803-6035
Cincinnati Children's Hospital Medical Center

Public Release: 22-Aug-2014
Cancer Epidemiology
Smokers consume same amount of cigarettes regardless of nicotine levels
Cigarettes with very low levels of nicotine may reduce addiction without increasing exposure to toxic chemicals, according to a new study from the University of Waterloo.

Contact: Pamela Smyth
psmyth@uwaterloo.ca
519-888-4777
University of Waterloo

Public Release: 22-Aug-2014
Journal of the National Cancer Institute
Scientists map risk of premature menopause after cancer treatment
Women treated for the cancer Hodgkin lymphoma will be able to better understand their risks of future infertility after researchers estimated their risk of premature menopause with different treatments. The findings, set out in the Journal of the National Cancer Institute, are based on the experience of more than 2,000 young women in England and Wales treated for the cancer over a period of more than 40 years.

Contact: Graham Shaw
henry.french@icr.ac.uk
020-715-35380
Institute of Cancer Research

Public Release: 22-Aug-2014
Inflammatory Bowel Diseases
Study shows epigenetic changes in children with Crohn's disease
A new study finds a wide range of epigenetic change -- alterations in DNA across the genome that may be related to key environmental exposures -- in children with Crohn's disease, reports Inflammatory Bowel Diseases, official journal of the Crohn's & Colitis Foundation of America. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

Contact: Connie Hughes
Connie.Hughes@wolterskluwer.com
646-674-6348
Wolters Kluwer Health

Public Release: 22-Aug-2014
Preventive Medicine
Women with severe, chronic health issues are screened for breast cancer less often
Women with severe disabilities and multiple chronic conditions are screened for breast cancer less often than women with no disabilities or no chronic conditions, a new study has found.

Contact: Geoff Koehler
koehlerg@smh.ca
416-864-6060 x6537
St. Michael's Hospital

Public Release: 22-Aug-2014
Journal of Thoracic Oncology
High concordance between EGFR mutations from circulating-free tumor DNA and tumor tissue in non-small cell lung cancer
Epidermal growth factor receptor mutations found in the circulating free tumor DNA from the plasma of advanced non-small cell lung cancer patients correlates well with the epidermal growth factor receptor mutations from patient-matched tumor tissue DNA.

Contact: Rob Mansheim
rob.mansheim@iaslc.org
720-325-2952
International Association for the Study of Lung Cancer

Public Release: 22-Aug-2014
Journal of Thoracic Oncology
Novel oncogenic RET mutation found in small cell lung cancer
For the first time an oncogenic somatic mutation at amino acid 918 in the rearranged during transfection protein has been identified in small cell lung cancer tumors and enforced expression of this mutation within small cell lung cancer tumor cell lines produced increased intracellular signaling and cell growth.

Contact: Rob Mansheim
rob.mansheim@iaslc.org
720-325-2952
International Association for the Study of Lung Cancer

Public Release: 22-Aug-2014
Journal of Thoracic Oncology
Deletion predicts survival in advanced non-small cell lung cancer
Bcl-2-like protein 11 deletion in advanced non-small cell lung cancer is associated with shorter progression free survival in epidermal growth factor receptor tyrosine kinase inhibitor or chemotherapy treated Asian patients. Also, Bcl-2-like protein 11 deletion independently predicts overall survival of advanced non-small cell lung cancer patients.

Contact: Rob Mansheim
rob.mansheim@iaslc.org
720-325-2952
International Association for the Study of Lung Cancer

Public Release: 22-Aug-2014
Cell Death & Disease
New enzyme targets for selective cancer therapies
A University of Alberta team has designed compounds that target brain cancer.

Contact: Bryan Alary
bryan.alary@ualberta.ca
780-492-0436
University of Alberta

Showing releases 26-50 out of 1244.

<< < 1 | 2 | 3 | 4 | 5 | 6 > >>

  Search News Releases

     

 

 

EurekAlert!